| |
All (n = 72)
|
No EUA (n = 42)
|
EUA (n = 30)
|
p-value
|
High citrulline (n = 25)
|
Low citrulline (n = 10)
|
p-value
|
|---|
|
Age (median, IQR)
|
68.8 (62.7–73.7)
|
69.0 (63.4–73.4)
|
67.8 (58.4–73.7)
|
0.479
|
69.3 (63.5–72.7)
|
63.6 (56.5–67.1)
|
0.07
|
|
Sex
|
|
male
|
45 (62)
|
26 (62%)
|
19 (63%)
|
0.902
|
16 (64%)
|
5 (50%)
|
0.445
|
|
female
|
27 (38)
|
16 (38%)
|
11 (37%)
| |
9 (36%)
|
5 (50%)
| |
|
Smoking status
|
|
current
|
29 (40)
|
20 (48%)
|
9 (30%)
|
0.062
|
11 (44%)
|
3 (30%)
|
0.534
|
|
former
|
34 (47)
|
15 (35%)
|
19 (63%)
| |
12 (48%)
|
5 (50%)
| |
|
never
|
9 (13)
|
7 (17%)
|
2 (7%)
| |
2 (8%)
|
2 (20%)
| |
|
Histological type
|
|
adenocarcinoma
|
45 (63)
|
27 (64%)
|
18 (60%)
|
0.592
|
19 (76%)
|
4 (40%)
|
0.019
|
|
squamous carcinoma
|
14 (19)
|
9 (22%)
|
5 (17%)
| |
5 (20%)
|
2 (20%)
| |
|
other
|
13 (18)
|
6 (14%)
|
7 (23%)
| |
1 (4%)
|
4 (40%)
| |
|
Mutational status
|
|
KRAS
|
26 (36)
|
12 (29%)
|
14 (47%)
|
0.292
|
10 (40%)
|
3 (30%)
|
0.394
|
|
EGFR
|
2 (3)
|
1 (2%)
|
1 (3%)
| |
1 (4%)
|
1 (10%)
| |
|
BRAF
|
3 (4)
|
1 (2%)
|
2 (7%)
| |
1 (4%)
|
2 (20%)
| |
|
None or rare mutation
|
41 (57)
|
28 (67%)
|
13 (43%)
| |
13 (52%)
|
4 (40%)
| |
|
Albumin
| | | |
0.889
| | |
0.104
|
|
< 30 g/l
|
12 (17)
|
7 (17)
|
5 (17)
| |
2 (8)
|
3 (30)
| |
|
≥ 30 g/l
|
57 (79)
|
32 (76)
|
25 (83)
| |
22 (88)
|
7 (70)
| |
|
unknown
|
3 (4)
|
3 (7)
|
0 (0)
| |
1 (4)
|
0 (0)
| |
|
Hemoglobin (median, IQR)
|
11.6 (10.0–12.7)
|
12.1 (11.3–13.0
|
10.5 (9.5–11.8)
|
0.006
|
12.3 (11.3–13.4)
|
9.9 (8.7–11.2)
|
0.006
|
|
Metastatic sites
|
|
brain
|
8 (11%)
|
5 (12%)
|
3 (10%)
|
0.800
|
6 (24%)
|
0
|
0.089
|
|
liver
|
10 (14%)
|
5 (12%)
|
5 (17%)
|
0.565
|
2 (8%)
|
2 (20%)
|
0.313
|
|
≥ 3 sites
|
16 (22%)
|
7 (17%)
|
9 (30%)
|
0.180
|
3 (12%)
|
2 (20%)
|
0.541
|
|
Stage
|
|
IIIB
|
10 (14)
|
5 (12%)
|
1 (3%)
|
0.195
|
3 (12%)
|
2 (20%)
|
0.541
|
|
IV
|
62 (86)
|
37 (88%)
|
29 (97%)
| |
22 (88%)
|
8 (80%)
| |
|
Performance status
|
|
0–1
|
45/71 (63)
|
27/41 (66%)
|
18 (60%)
|
0.216
|
22 (88%)
|
3 (30%)
|
0.001
|
|
2
|
26/71 (37)
|
14/41 (34%)
|
12 (40%)
| |
3 (12%)
|
7 (70%)
| |
|
Number of lines before nivolumab
|
|
1
|
62 (86%)
|
37 (88%)
|
26 (87%)
|
0.587
|
22 (88%)
|
9 (90%)
|
0.867
|
|
> 2
|
10 (14)
|
5 (12%)
|
4 (13%)
| |
3 (12%)
|
1 (10%)
| |
|
PD-L1 IHC
|
|
< 1%
|
8 (11)
|
6 (14)
|
2 (7)
|
0.072
|
6 (24)
|
2 (20)
|
0.900
|
|
≥ 1%
|
15 (21)
|
5 (12)
|
10 (33)
| |
11 (44)
|
4 (40)
| |
|
unknown
|
49 (68)
|
31 (74)
|
18 (60)
| |
8 (32)
|
4 (40)
| |
- EUA early use of antibiotics. Variables expressed as n (%) unless otherwise specified. High citrulline: ≥20 μM; low citrulline: < 20 μM. P-values calculated by Mann-Whitney test or Chi2 test
